Top Page
DENTSPLY SIRONA
(NASDAQ:XRAY)
DENTSPLY SIRONA (XRAY) vs. SPDR S&P 500 ETF (SPY)
DENTSPLY SIRONA Business Overview & Revenue Model
DENTSPLY SIRONA Key Performance Indicators (KPIs)
Reveals profitability across different business segments, highlighting which areas drive earnings and where operational efficiencies or challenges exist.
Main Street DataDENTSPLY SIRONA Earnings Call Summary
DENTSPLY SIRONA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.79B | 3.96B | 3.92B | 4.25B | 3.34B |
| Gross Profit | 1.90B | 1.96B | 2.09B | 2.13B | 2.36B | 1.66B |
| EBITDA | -692.00M | -518.00M | 232.00M | -677.00M | 972.00M | 336.00M |
| Net Income | -949.00M | -910.00M | -132.00M | -950.00M | 411.00M | -83.00M |
Balance Sheet | ||||||
| Total Assets | 6.07B | 5.75B | 7.37B | 7.64B | 9.22B | 9.34B |
| Cash, Cash Equivalents and Short-Term Investments | 359.00M | 272.00M | 334.00M | 365.00M | 339.00M | 438.00M |
| Total Debt | 2.49B | 2.27B | 2.30B | 2.09B | 2.24B | 2.41B |
| Total Liabilities | 4.11B | 3.81B | 4.08B | 3.83B | 4.18B | 4.37B |
| Stockholders Equity | 1.96B | 1.94B | 3.29B | 3.81B | 5.04B | 4.97B |
Cash Flow | ||||||
| Free Cash Flow | 138.00M | 281.00M | 228.00M | 368.00M | 515.00M | 548.00M |
| Operating Cash Flow | 283.00M | 461.00M | 377.00M | 517.00M | 657.00M | 635.00M |
| Investing Cash Flow | -155.00M | -197.00M | -89.00M | -138.00M | -358.00M | -1.11B |
| Financing Cash Flow | -62.00M | -302.00M | -307.00M | -329.00M | -379.00M | 490.00M |
DENTSPLY SIRONA Technical Analysis
DENTSPLY SIRONA Risk Analysis
DENTSPLY SIRONA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $13.69B | 33.97 | 5.01% | ― | 6.35% | 12.94% | |
71 Outperform | $35.97B | 25.22 | 25.41% | 0.87% | 9.36% | 29.56% | |
70 Outperform | $51.32B | 32.20 | 6.26% | 2.35% | 7.86% | 14.24% | |
69 Neutral | $16.52B | 29.86 | 11.12% | ― | 1.74% | -25.29% | |
53 Neutral | $9.22B | ― | -4.70% | 3.79% | -21.20% | -325.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
39 Underperform | $2.49B | ― | -37.78% | 5.81% | -5.78% | -445.83% |
DENTSPLY SIRONA Corporate Events
Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, is renowned for its innovative solutions that advance patient care and enhance dental services globally. The company, headquartered in Charlotte, North Carolina, operates in the dental and medical device sectors, offering a comprehensive range of dental and oral health products.
DENTSPLY SIRONA’s recent earnings call painted a challenging picture, marked by a decline in global and U.S. sales, an impairment charge, and a drop in EPS. Despite some positive developments, such as growth in European sales and Wellspect Healthcare, the overall sentiment was negative due to the financial difficulties and strategic hurdles the company faces. The focus was on a turnaround strategy to navigate these pressing issues.
On October 31, 2025, DENTSPLY SIRONA Inc. announced that Matthew E. Garth will step down from his role as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun searching for a new CFO and clarified that Garth’s departure is not due to any disagreements regarding the company’s financial practices. Concurrently, Daniel T. Scavilla, the company’s President and CEO, will take on the additional role of interim principal financial officer. This transition is not expected to involve any new compensatory arrangements for Scavilla.
The most recent analyst rating on (XRAY) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
On October 14, 2025, DENTSPLY SIRONA announced that the SEC has concluded its investigation, which began in May 2022, into the company’s financial reporting matters without recommending any enforcement action. This closure is seen as a significant and favorable development for the company, reflecting its cooperation with the SEC and potentially strengthening its position in the industry.
The most recent analyst rating on (XRAY) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
On October 2, 2025, DENTSPLY SIRONA announced that Richard C. Rosenzweig will transition from his role as Executive Vice President, Corporate Development, General Counsel, and Secretary to a non-executive position as Special Legal Advisor, effective October 3, 2025. This transition is part of a mutual agreement, and Mr. Rosenzweig will continue to serve in an advisory capacity until March 4, 2026, with a monthly fee and additional severance benefits, before becoming an independent contractor consultant for a year.
The most recent analyst rating on (XRAY) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
On September 19, 2025, DENTSPLY SIRONA‘s Board approved a one-time retention equity incentive award for executives, including Tony Johnson, to recognize his performance during a leadership transition. The award, valued at $2 million in stock options, aims to retain Johnson for three years, with options vesting on the third anniversary and expiring ten years from the grant date.
The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
On September 8, 2025, Dentsply Sirona announced the completion of its strategic review of the Wellspect Healthcare business, deciding to retain it within its portfolio. This decision follows extensive evaluation and outreach, concluding that Wellspect, a leader in the global continence care market, will deliver greater financial and strategic benefits to stockholders as part of Dentsply Sirona, given its strong product pipeline and market potential.
The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.
DENTSPLY SIRONA’s latest earnings call reflected a challenging quarter marked by declines in sales across several regions and segments, particularly in the U.S. and CTS segment. Despite these hurdles, there were areas of stability and growth, such as the DS Core platform and Germany’s sales performance. However, the significant impact of tariffs and impairment charges weighed heavily on the overall sentiment.
Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, reported its second quarter 2025 financial results, highlighting a decrease in net sales and a leadership transition. The company, known for its innovative dental solutions, operates in the healthcare sector with a strong global presence.